908 Devices, Inc. (MASS)
| Market Cap | 283.30M |
| Revenue (ttm) | 26.89M |
| Net Income (ttm) | -12.91M |
| Shares Out | 5.49M |
| EPS (ttm) | -2.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $51.65 |
| Previous Close | $51.03 |
| Change ($) | 0.62 |
| Change (%) | 1.21% |
| Day's Open | 51.18 |
| Day's Range | 50.62 - 53.19 |
| Day's Volume | 153,012 |
| 52-Week Range | 38.88 - 79.60 |
BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- 908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it w...
BOSTON--(BUSINESS WIRE)--Experienced HR executive with global tech background joins executive leadership team
BOSTON--(BUSINESS WIRE)--Agency selected the MX908 to work closely with local law enforcement to prevent drug smuggling as opioid crisis rages across the country.
908 Devices expects 45% revenue growth this year. About 8% below its IPO price, MASS could be a good bet.
908 Devices Inc (NASDAQ: MASS) is seen as a high-growth life science tools company that analysts at SVB Leerink expect to “outperform” despite conservative 2021 guidance given by its management due to t...
2020 Revenue Increased 50% Over Prior Year 2020 Revenue Increased 50% Over Prior Year
Multi-mission device will support field teams with trace detection point of need analysis Multi-mission device will support field teams with trace detection point of need analysis
Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.
BOSTON--(BUSINESS WIRE)--Company adds two directors with financial, pharmaceutical, and consumable business expertise.
BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financi...
BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will participate in...
BOSTON--(BUSINESS WIRE)--Bioprocess Veteran Steve Davenport joins company as Vice President of Commercial Sales.
BOSTON--(BUSINESS WIRE)--908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the closing of its upsized initial pu...
908 Devices is a very interesting business with great potential and recent operating momentum. Expectations have risen quite a bit after a big opening day move higher; I still like the long-term potential.
Shares of 908 Devices Inc. more than doubled on their public debut, as the Massachusetts-based biochemical analysis device company's stock opened 127.6% above the upsized initial public offering's price...
Research device maker prices shares at $20 each.
BOSTON--(BUSINESS WIRE)--908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of its upsized initial pu...
908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that it has filed a registration statement on Form S-1 with the U.S...
908 Devices, which provides a suite of mass spectrometry devices for scientific research, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering.
908 Devices, Inc. has filed to go public with an IPO on the NASDAQ.
About MASS
908 Devices has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Leveraging our proprietary platform technology, we make the extraordinary analytical power of Mass Spec available in devices that are significantly smaller and more accessible than conventional laboratory instruments. Our Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical p... [Read more...]
| Industry Medical Devices | IPO Date Dec 18, 2020 |
| CEO Kevin J. Knopp | Employees 101 |
| Stock Exchange NASDAQ | Ticker Symbol MASS |
Financial Performance
In 2020, 908 Devices's revenue was $26.89 million, an increase of 49.64% compared to the previous year's $17.97 million. Losses were -$12.82 million, -4.14% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for 908 Devices stock is "Strong Buy." The 12-month stock price forecast is 67.50, which is an increase of 30.69% from the latest price.